Mark Cuban, Co-founder of Cost Plus Drugs, Calls for Texas to Disclose Drug Price Contracts
Mark Cuban, co-founder of Cost Plus Drugs, testified at the Texas legislature, calling for cash purchase rebates, standardization of PBM contracts, price transparency, elimination of confidentiality clauses, and strengthened penalties to rebuild price competition in the prescription drug market.
He stated that many Cost Plus Drugs users have insurance but still choose to pay cash for medications because the cash price of some prescriptions is lower than the out-of-pocket costs required by their insurance plans. This means that the same drug could have a "$500 insurance price and a $100 cash price" discrepancy, where patients opting for the lower cash price may not receive credit towards their insurance deductibles or annual out-of-pocket maximums.
Cuban urged Texas to allow patients to purchase medications at lower cash prices within its jurisdiction and to count the actual amounts paid towards insurance deductibles and out-of-pocket maximums. This design would incentivize patients to compare drug prices: if the cash price is lower than the insurance settlement price, patients choosing cash would not be penalized by losing subsequent insurance benefits.
He suggested that the Texas government, cities, counties, and school districts adopt standardized contracts for pharmacy benefit managers (PBMs) and third-party administrators (TPAs). Cuban noted that some contracts are hundreds or even over a thousand pages long, making it difficult for purchasers to identify hidden economic benefits in rebates, price differences, pharmacy reimbursements, related party compensations, performance guarantees, and audit rights.
Cuban called for the disclosure of drug prices, management fees, rebates, performance guarantees, pharmacy reimbursement prices, related company compensations, and audit rights for publicly funded payments, excluding patient information or real safety information. He believes that once contract information is made public, competitors can bid based on known prices and service conditions, providing taxpayers, employers, and patients with a basis for negotiation.
He also demanded the elimination of "gag clauses" in PBM contracts. Such clauses may restrict employers from comparing different PBM quotes, rebates, fees, and pharmacy reimbursement conditions, preventing buyers from making horizontal comparisons; Cuban likened them to "no-discussion rules" in contracts, arguing that they obstruct the price discovery necessary for a normal market.
In terms of enforcement, he suggested that healthcare companies should receive one chance to correct after a serious violation, but if a second significant federal or Texas enforcement action occurs within a specified timeframe, they should lose eligibility for new Texas government contracts for a period. He also advocated for increased budgets for audits and claims analysis, stating that spending $10 million to prevent $100 million in unnecessary expenditures would yield a tenfold return on public funds.
In terms of market mechanisms, patients, employers, state governments, and public employee health plans are the buyers of drug payments; pharmaceutical companies, pharmacies, insurance companies, PBMs, TPAs, and distribution systems constitute the sellers and intermediaries. Price transparency, cash price rebates, and standardized contracts would shift funds from opaque rebates, price differences, and related party charges to lower front-end drug prices, patient out-of-pocket savings, and public bidding; PBMs and vertically integrated healthcare groups profiting from opaque contract structures would face pressure, while transparent pricing pharmacies, generic drug suppliers, and competitors offering lower net prices would benefit.
Source: Public Information
ABAB AI Insight
Cuban founded Mark Cuban Cost Plus Drug Company in 2022, focusing on bypassing the traditional PBM-dominated complex pricing chain by collaborating directly with manufacturers and selling large quantities of generic drugs at publicly available procurement prices with fixed markups and pharmacy service fees. The target of this model is not the drug development itself, but the price differences, rebates, and management fees that patients, employers, and public purchasers cannot see in prescription drug payments. Cuban's testimony transforms the business model into public procurement rules: not only allowing users to purchase drugs from Cost Plus but also requiring Texas to change the visibility and comparability of all public healthcare contracts.
The core of the capital path is that PBMs control the financial settlements between pharmaceutical companies, insurance plans, employers, pharmacies, and patients. Pharmaceutical companies provide rebates in exchange for formulary positions, PBMs negotiate net prices with insurance plans, pharmacies receive payments based on a different reimbursement standard, and patients pay according to copayments, coinsurance, or deductibles; if buyers can only see partial quotes, PBMs and related entities can retain profits in rebates, price differences, prescription steering, and pharmacy services. Allowing cash purchases to count towards deductibles effectively enables cash prices to compete directly with insurance settlement prices, transforming patients from passive payers into purchasers with choices in payment paths.
Historically, the U.S. pharmacy benefit management industry has evolved from helping insurance plans process prescription claims and drug formularies to a highly vertically integrated payment system. CVS Health owns Caremark PBM, insurance company Aetna, and a retail pharmacy network; Cigna owns Express Scripts; UnitedHealth's Optum covers insurance, PBM, pharmacy, and healthcare services. This integration can reduce coordination costs but also makes it difficult for purchasers to disaggregate the income obtained by the same group at different stages. The direction promoted by Cuban and Texas politician James Talarico towards antitrust and transparency is aimed at addressing this structure where "one group simultaneously represents the payer, negotiator, and service provider."
This represents a shift in pricing power. The ultimate payers for prescription drugs are patients, employers, and taxpayers, but in the traditional system, they often cannot see net prices, rebates, and contract terms, with actual pricing power falling into the hands of PBMs and vertically integrated groups that control transaction data and contract design due to information asymmetry. Making prices public and allowing patients to accumulate deductibles with lower cash prices would return the comparative power to buyers; standardizing contracts would transform the scale of government procurement into bargaining power; and limiting government contract eligibility after a second significant violation would turn fines from costs that can be included in operating expenses into substantial risks affecting future cash flows.
ABAB News · Cognitive Laws
- Invisible prices are always set by intermediaries.
- Rebates lower apparent costs, while price differences raise real costs.
- Public contracts are not transparent; they return bargaining power to buyers.